Restricted accessResearch articleFirst published online 2023-04
Cannabidiol as a Treatment for Neurobiological,Behavioral,and Psychological Symptoms in Early-Stage Dementia: A Double-Blind,Placebo-Controlled Clinical Trial Protocol
The slowing of disease progression in dementia in the early stages of diagnosis is paramount to improving the quality of life for those diagnosed and their support networks. Accumulating evidence suggests that CBD, a constituent of Cannabis sativa, is associated with neuroprotective, neuroendocrine, and psychotherapeutic effects, suggesting that it may be beneficial to dementia treatment. However, no published human study to date has examined this possibility. This trial aims to determine whether daily treatment with CBD over a 12-week period is associated with improved neurobiological, behavioral, and psychological outcomes in individuals living with early-stage dementia.
Methods:
Sixty participants with early-stage dementia will be recruited for a randomized, double-blind, placebo-controlled clinical trial. Participants will be randomized into either 99.9% pure CBD or placebo treatment conditions and administered two capsules per day for 12 weeks. Participants will commence a 200 mg/day dose for 2 weeks before escalating to 300 mg/day for the remaining 10 weeks. Neuroimaging and blood-based neuroendocrine profiles will be assessed at baseline and post-treatment. Psychological and behavioral symptoms will be assessed at baseline, 6 weeks, and post-treatment. Monitoring of health and side-effects will be conducted through weekly home visits.
Discussion:
This study is among the first to investigate the effects of isolated CBD in improving neuroanatomical and neuroendocrine changes, alongside psychological symptoms, during the early stages of dementia diagnosis. The outcomes of this trial have the capacity to inform a potential novel and accessible treatment approach for individuals living with early-stage dementia, and in turn, improve quality of life, prognoses, and treatment outcomes.
Trial Registration:
This trial has been registered with the Therapeutic Goods Administration (CT-2020-CTN-03849-1v2) and the Australian and New Zealand Clinical Trials Registry (ACTRN12621001364864).
Get full access to this article
View all access options for this article.
References
1.
RazL, KnoefelJ, BhaskarK. The neuropathology and cerebrovascular mechanisms of dementia. J Cereb Blood Flow Metab. 2016; 36:172–186.
2.
GhoshA. Endocrine, metabolic, nutritional, and toxic disorders leading to dementia. Ann Indian Acad Neurol. 2010; 13:S63–S68.
3.
GrandJ, CasparS, MacDonaldS. Clinical features and multidisciplinary approaches to dementia care. J Multidiscip Healthc. 2011; 4:125–147.
4.
SeitzD, GillS, HerrmanN, et al.Pharmacological treatments for neuropsychiatric symptoms of dementia in long-term care: a systematic review. Int Psychogeriatr. 2013; 25:185–203.
5.
BeedhamW, SbaiM, AllisonI, et al.Cannabinoids in the older person: a literature review. Geriatrics. 2020; 5:5010002.
6.
Medina-VeraD, Rosell-ValleC, Lopez-GamberoAJ, et al.Imbalance of endocannabinoid/lysophosphatidylinositol receptors marks the severity of Alzheimer's disease in a preclinical model: a therapeutic opportunity. Biology. 2020; 9:1–22.
7.
WattG, KarlT. In vivo evidence for therapeutic properties of cannabidiol (CBD) for Alzheimer's disease. Front Pharmacol. 2017; 8:1–7.
HallinanC, GunnJ, BonomoY. Implementation of medicinal cannabis in Australia: innovation or upheaval? Perspectives from physicians as key informants, a qualitative analysis. BMJ Open. 2021; 11:e054044.
11.
HallinanC, EdenE, GrahamM, et al.Over the counter low-dose cannabidiol: A viewpoint from the ACRE Capacity Building Group. J Psychopharmacol. 2022; 36:661–665.
12.
CrippaJ, GuimaraesF, CampsA, et al.Translational investigation of the therapeutic potential of cannabidiol (CBD): toward a new age. Front Immunol. 2018; 9:2009.
13.
CastilloA, TolonM, Fernandez-RuizJ, et al.The neuroprotective effect of cannabidiol in an in vitro model of newborn hypoxic-ischemic brain damage in mice is mediated by CB2 and adenosine receptors. Neurobiol Dis. 2010; 37:434–440.
14.
CamposA, FogaçaM, ScaranteF, et al.Plastic and neuroprotective mechanisms involved in the therapeutic effects of cannabidiol in psychiatric disorders. Front Pharmacol. 2017; 8:269.
15.
OsborneA, SolowijN, BabicI, et al.Improved social interaction, recognition and working memory with cannabidiol treatment in a prenatal infection (poly I:C) rat model. Neuropsychopharmacology. 2017; 42:1447–1457.
16.
WangZ, ZhengP, XieY, et al.Cannabidiol regulates CB1-pSTAT3 signaling for neurite outgrowth, prolongs lifespan and improves health span in Caenorhabditis elegans of Aβ models. FASEB J. 2021; 35:e21537.
17.
YücelM, LorenzettiV, SuoC, et al.Hippocampal harms, protection and recovery following regular cannabis use. Transl Psychiatry. 2016; 6:e710.
18.
BealeC, BroydS, ChyeY, et al.Prolonged cannabidiol treatment effects on hippocampal subfield volumes in current cannabis users. Cannabis Cannabinoid Res. 2018; 3:94–107.
19.
AtalayS, Jarocka-KarpowiczI, SkrzydlewskaE. Antioxidative and anti-inflammatory properties of cannabidiol. Antioxidants. 2020; 9:21.
20.
BorowskaM, CzarnywojtekA, Sawicka-GutajN, et al.The effects of cannabinoids on the endocrine system. Endokrynol Pol. 2018; 69:705–719.
21.
ZuardiA, GuimaraesF, MoreiraA. Effect of cannabidiol on plasma prolactin, growth hormone and cortisol in human volunteers. Braz J Med Biol Res. 1993; 26:213–217.
22.
SpohnS, MaweG. Non-conventional features of peripheral serotonin signaling. Nat Rev Gastroenterol Hepatol. 2017; 14:412–420.
23.
SugiuraT, DohiY, YamashitaS, et al.Serotonin in peripheral blood reflects oxidative stress and plays a crucial role in atherosclerosis: novel insights into holistic and anti-atherothrombotic strategy. Atherosclerosis. 2016; 246:157–160.
24.
BaumeisterD, RussellA, ParianteC, et al.Inflammatory biomarker profiles of mental disorders and their relation to clinical, social, and lifestyle factors. Soc Psychiatry Psychiatr Epidemiol. 2014; 49:841–849.
25.
MoreiraF, GuimaraesF. Cannabidiol inhibits the hyperlocomotion induced by psychotomimetic drugs in mice. Eur J Pharmacol. 2005; 512:199–205.
26.
CorroonJ, PhillipsJ. A cross-sectional study of cannabidiol users. Cannabis Cannabinoid Res. 2018; 3:152–161.
27.
BergamaschiM, QueirozR, ChagasM, et al.Cannabidiol reduces the anxiety induced by simulated public speaking in treatment naïve social phobia patients. Neuropsychopharmacology. 2011; 36:1219–1226.
28.
PremoliM, AriaF, BoniniS, et al.Cannabidiol: recent advances and new insights for neuropsychiatric disorders and treatment. Life Sci. 2019; 224:120–127.
29.
SolowijN, BroydS, BealeC, et al.Therapeutic effects of prolonged cannabidiol treatment on psychological symptoms and cognitive function in regular cannabis users: a pragmatic open-label clinical trial. Cannabis Cannabinoid. Res. 2018; 3:21–34.
30.
TimlerA, BulsaraC, BulsaraM, et al.Examining the use of cannabinoid-based medicine among older residential care recipients diagnosed with dementia: a study protocol for double blind randomised cross over trial. Trials BMC. 2020; 21:188.
31.
ShelefA, BarakY, BergerU, et al.Safety and efficacy of medical cannabis oil for behavioural and psychological symptoms of dementia: an open label, add-on, pilot study. J Alzheimer's Dis. 2016; 51:15–19.
32.
Van den ElsenG, TobbenL, AhmedA, et al.Effects of tetrahydrocannabinol on balance and gait in patients with dementia: a randomised controlled crossover trial. J Psychopharmacol. 2017; 31:184–191.
JuttenR, HarrisonJ, de JongF, et al.A composite measure of cognitive and functional progression in Alzheimer's disease: design of the Capturing Changes in Cognition study. Alzheimer's Dement Transl Res Clin Interv. 2017; 3:130–138.
35.
DuboisB, SlachevskyA, LitvanI, et al.The FAB: a frontal assessment battery at bedside. Neurology. 2000; 55:1621–1626.
36.
SheikhJ, YesavageJ. Geriatric Depression Scale (GDS): recent evidence and development of a shorter version. Clin Gerontol. 1986; 5:165–173.
37.
ShankarK, WalkerM, FrostD, et al.The development of a valid and reliable scale for Rating Anxiety in Dementia (RAID). Aging Ment Health, 1999; 3:39–49.
38.
LogsdonR, GibbonsL, McCurryS, et al.Quality of life in Alzheimer's disease: patient and caregiver reports. J Ment Health Aging. 1999; 5:21–32.
39.
BucksR, AshworthD, WilcockG, et al.Assessment of daily living activities in dementia: development of the Bristol Activities of Daily Living Scale. Age Ageing. 1996; 25:113–120.
40.
KauferD, CummingsJ, KetchelP, et al.Validation of the NPI-Q, a brief clinical form of the Neuropsychiatric Inventory. J Neuropsychiatry Clin Neurosci. 2000; 12:233–239.
41.
IkedaM, BrownJ, HollandA, et al.Changes in appetite, food preference and eating habits in frontotemporal dementia and Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2002; 73:371–376.
42.
TractenbergR, SingerC, CummingsJ, et al.The Sleep Disorders Inventory: an instrument for studies of sleep disturbance in persons with Alzheimer's disease. J Sleep Res. 2003; 12:331–337.
43.
FinkelS, LyonsJ, AndersonR. A Brief Agitation Rating Scale (BARS) for nursing home elderly. J Am Geriatr Soc. 1993; 41:50–52.
44.
PatelV, HopeR. A Rating Scale for Aggressive Behaviour in the Elderly—The RAGE. Psychol Med. 1992; 22:211–221.
45.
ChanA, TetzlaffJ, GotzscheP, et al.SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ. 2013; 346:e7586.
46.
ReisbergB, FerrisS, de LeonM, et al.The global deterioration scale for assessment of primary degenerative dementia. Am J Psychiatry. 1982; 139:1136–1139.
47.
FolsteinM, FolsteinS, McHughP. ‘Mini-mental state’. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975; 12:189–198.
48.
KimS, CaineE. Utility and limits of the Mini Mental State Examination in evaluating consent capacity in Alzheimer's disease. Psychiatr Serv. 2002; 53:1322–1324.
49.
IfflandK, GrotenhermenF. An update on safety and side effects of cannabidiol: a review of clinical data and relevant animal studies. Cannabis Cannabinoid Res. 2017; 2:139–154.
50.
ChesneyE, OliverD, GreenA, et al.Adverse effects of cannabidiol: a systematic review and meta-analysis of randomised clinical trials. Neuropsychopharmacology. 2020; 45:1799–1806.
51.
LarsenC, ShahinasJ. Dosage, efficacy and safety of cannabidiol administration in adults: a systematic review of human trials. J Clin Res Med. 2020; 12:129–141.
BergamaschiM, QueirozR, CrippaJ, et al.Safety and side effects of cannabidiol, a Cannabis sativa constituent. Curr Drug Saf. 2011; 6:1–13.
54.
BrownJ, WintersteinA. Potential adverse drug events and drug-drug interactions with medical and consumer cannabidiol (CBD) use. J Clin Med. 2021; 8:1–14.
BhattacharyyaS, MorrisonP, Fusar-PoliP, et al.Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology. 2010; 35:764–774.
57.
Fusar-PoliP, CrippaJ, BhattacharyyaS, et al.Distinct effects of delta 9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing. Arch Gen Psychiatry. 2009; 66:95–105.
58.
HallakJ, Machado-de-SousaJ, CrippaJ, et al.Performance of schizophrenic patients in the Stroop Color Word Test and electrodermal responsiveness after acute administration of cannabidiol (CBD). Rev Bras de Psiquitaria. 2010; 32:56–61.
59.
SiloteG, SartimA, SalesA, et al.Emerging evidence for the antidepressant effect of cannabidiol and the underlying molecular mechanisms. J Clin Neuroanat. 2019; 98:104–116.
60.
RiederC. Cannabidiol in Parkinson's disease. Braz J Psychiatry. 2020; 42:126–127.
61.
ZuardiA, RodriguesN, SilvaA, et al.Inverted U-shaped dose-response curve of the anxiolytic effect of cannabidiol during public speaking in real like. Front Pharmacol. 2017; 8:259.
62.
BoggsD, SurtiT, GuptaA, et al.The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia: a randomised placebo-controlled trial. Psychopharmacology. 2018; 235:1923–1932.
63.
LewekeF, PiomelliD, PahlischF, et al.Cannabidiol enhances anandamide signalling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry. 2012; 2:e94.
64.
BergerM, LiE, AmmingerG. Treatment of social anxiety disorder and attenuated psychotic symptoms with cannabidiol. BMJ Case Rep. 2020; 13:e235307.
65.
McPartlandJ, DuncanM, Di MarzoV, et al.Are cannabidiol and Δ(9)—Tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review. Br J Pharmacol. 2015; 172:737–753.
66.
McGuireP, RobsonP, CubalaW, et al.Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: a multicentre randomised controlled trial. Am J Psychiatry. 2018; 175:225–231.
67.
StoreyJ, RowlandJ, BasicD, et al.The Rowland Universal Dementia Assessment Scale (RUDAS): a multicultural cognitive assessment scale. Int Psychogeriatr. 2004; 161:13–31.
68.
SheehanD. Mini International Neuropsychiatric Interview 7.0. Medical Outcomes Systems: Jacksonville, FL; 2015.
69.
AtkinsonM, SinhaA, HassS, et al.Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes. 2004; 2:1–12.
70.
HurstH, BoltonJ. Assessing the clinical significance of change scores recorded on subjective outcome measures. J Manipulative Physiol Ther. 2004; 27:26–35.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
